Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 301

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

NONPALPABLE STAGE T1C PROSTATE CANCER: PREDICTION OF INSIGNIFICANT DISEASE USING FREE/TOTAL PROSTATE SPECIFIC ANTIGEN LEVELS AND NEEDLE BIOPSY FINDINGS

EPSTEIN, JONATHAN I., CHAN, DANIEL W., SOKOLL, LORI J., WALSH, PATRICK C., COX, JENNIFER L., RITTENHOUSE, HARRY, WOLFERT, ROBERT, CARTER, H. BALLENTINE · 1998 · Journal of Urology

Abstract

PURPOSE: Approximately 25% of radical prostatectomies performed for stage T1c disease show potentially insignificant prostate cancer. We previously reported the use of serum prostate specific antigen (PSA) density and needle biopsy findings to predict potentially insignificant cancer. We now evaluate whether using free/total serum PSA levels along with needle biopsy findings can better predict tumor significance. MATERIALS AND METHODS: We studied 163 radical prostatectomy specimens of stage T1c prostate cancer in which free/total serum PSA levels were determined. Free/total serum PSA levels were measured with Tandem-MP PSA assays. Insignificant prostate cancers were organ confined with tumor volumes less than 0.5 cc and Gleason score less than 7. Advanced tumors were either Gleason score 7 or greater, established extraprostatic extension with positive margins, or positive seminal vesicles or lymph nodes. Other cases were considered as moderate tumor. Moderate and advanced tumors were considered significant. RESULTS: Of the tumors 30.7% were insignificant, 49.7% moderate and 19.6% advanced. The best model to predict preoperatively insignificant tumor was a free/total PSA of 0.15 or greater and favorable needle biopsy findings (less than 3 cores involved, none of the cores with greater than 50% tumor involvement and Gleason score less than 7). Using this model of the 18 tumors predicted to be insignificant 17 were insignificant for a positive predictive value of 94.4%. Of the 145 cases that were predicted to be significant 112 were correctly predicted for a negative predictive value of 77.2%. There was only 1 tumor predicted to be insignificant which was classified as moderate. No tumor predicted to be insignificant was advanced. CONCLUSIONS: In conjunction with needle biopsy findings, free/total PSA levels accurately predict insignificant tumor in stage T1c disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0022-5347(01)62200-6

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 301

Metadata

Authors
EPSTEIN, J. I., CHAN, D. W., SOKOLL, L. J., WALSH, P. C., COX, J. L., RITTENHOUSE, H., WOLFERT, R., & CARTER, H. B.
Venue
Journal of Urology
Published
1998-12
Volume
160
Issue
6 Part 2
Pages
2407-2411
ISSN
  • 0022-5347 (ISSN-L)
  • 1527-3792
OpenAlex
W2145491305
Cited by
301
References
1
FWCI
7.61
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NONPALPABLE STAGE T1C PROSTATE CANCER: PREDICTION OF INSIGNIFICANT DISEASE USING FREE/TOTAL PROSTATE SPECIFIC ANTIGEN LEVELS AND NEEDLE BIOPSY FINDINGS. https://app.cochat.ai/papers/10.1016/s0022-5347(01)62200-6
The paper
EPSTEIN, J. I., CHAN, D. W., SOKOLL, L. J., WALSH, P. C., COX, J. L., RITTENHOUSE, H., WOLFERT, R., & CARTER, H. B. (1998). NONPALPABLE STAGE T1C PROSTATE CANCER: PREDICTION OF INSIGNIFICANT DISEASE USING FREE/TOTAL PROSTATE SPECIFIC ANTIGEN LEVELS AND NEEDLE BIOPSY FINDINGS. Journal of Urology. https://doi.org/10.1016/s0022-5347(01)62200-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.